Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hemispherx’s Ampligen Poised To Become First Approval For Chronic Fatigue Syndrome

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA staff scheduling changes are behind a 1-2 week delay of action on May 25 user fee goal.

You may also be interested in...



Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"

FDA wants more of everything, from clinical trials to resolution of manufacturing issues.

Chronic Fatigue Drug Moving Slowly: Hemispherx's Ampligen Gets "Complete Response"

FDA wants more of everything, from clinical trials to resolution of manufacturing issues.

Chronic Fatigue Drug Moving Slowly: Ampligen Gets "Complete Response"

FDA's "complete response" letter for Hemispherx Biopharma's Ampligen cites the full gamut of problems that could have come up for the NDA

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel